Daniel Paul Koch

US Patent:

6358972, Mar 19, 2002

Filed:

Dec 5, 2000

Appl. No.:

09/701934

Inventors:

Sandra Ann Filla - Franklin IN
Daniel James Koch - Indianapolis IN
Brian Michael Mathes - Indianapolis IN
Vincent Patrick Rocco - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31435

US Classification:

514300, 546113

Abstract:

The present invention relates to a compound of formula (I): or a pharmaceutical acid addition salt thereof; which is useful for activating 5-HT receptors and inhibiting protein extravasation in a mammal.

US Patent:

7144898, Dec 5, 2006

Filed:

Dec 6, 2000

Appl. No.:

10/149476

Inventors:

Marvin Martin Hansen - Indianapolis IN, US
John Xiaoqiang He - Fishers IN, US
Nicholas Allan Honigschmidt - Brownsburg IN, US
Daniel James Koch - Indianapolis IN, US
Todd Jonathan Kohn - Fishers IN, US
Vincent Patrick Rocco - Indianapolis IN, US
Patrick Gianpietro Spinazze - Avon IN, US
Kumiko Takeuchi - Indianapolis IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A11K 31/445

US Classification:

514319, 514277, 546201, 546202, 546192, 546195, 546184

Abstract:

The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.

US Patent:

63036274, Oct 16, 2001

Filed:

Jun 3, 1999

Appl. No.:

9/325302

Inventors:

Daniel James Koch - Indianapolis IN
Vincent Patrick Rocco - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 3144
A61K 31445
C07D40100
C07D21520
C07D21516

US Classification:

514307

Abstract:

This invention provides compounds and a method for the inhibition of serotonin reuptake in mammals.

US Patent:

60462159, Apr 4, 2000

Filed:

Jul 30, 1998

Appl. No.:

9/126572

Inventors:

James E. Audia - Indianapolis IN
Daniel J. Koch - Indianapolis IN
Thomas E. Mabry - Indianapolis IN
Jeffrey S. Nissen - Indianapolis IN
Vincent P. Rocco - Indianapolis IN
Yao-Chang Xu - Fishers IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 3144
C07D40904

US Classification:

514337

Abstract:

This invention provides compounds and a method for the inhibition of serotonin reuptake in mammals.

US Patent:

58469826, Dec 8, 1998

Filed:

May 22, 1997

Appl. No.:

8/862208

Inventors:

James E. Audia - Indianapolis IN
Daniel J. Koch - Indianapolis IN
Thomas E. Mabry - Indianapolis IN
Jeffrey S. Nissen - Indianapolis IN
Vincent P. Rocco - Indianapolis IN
Yao-Chang Xu - Fishers IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 3143
A61K 3144
C07D40904
C07D40104

US Classification:

514318

Abstract:

This invention provides compounds and a method for the inhibition of serotonin reuptake in mammals.

US Patent:

57080089, Jan 13, 1998

Filed:

Mar 20, 1996

Appl. No.:

8/619783

Inventors:

James Edmund Audia - Indianapolis IN
Bruce Anthony Dressman - Indianapolis IN
James Joseph Droste - Indianapolis IN
James Erwin Fritz - Greenwood IN
Stephen Warren Kaldor - Indianapolis IN
Daniel James Koch - Indianapolis IN
Joseph Herman Krushinski - Indianapolis IN
Jeffrey Scott Nissen - Indianapolis IN
Vincent Patrick Rocco - Indianapolis IN
John Mehnert Schaus - Zionsville IN
Dennis Charles Thompson - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31445
C07D40104

US Classification:

514323

Abstract:

This invention provides novel 5-HT. sub. 1F agonists of Formula I ##STR1## where A--B, R, R. sup. 1 and X are as defined in the specification, which are useful for the treatment of migraine and associated disorders.

US Patent:

59122560, Jun 15, 1999

Filed:

May 22, 1997

Appl. No.:

8/861445

Inventors:

Daniel James Koch - Indianapolis IN
Vincent Patrick Rocco - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31445
A61K 31495
C07D40114

US Classification:

514323

Abstract:

A series of 1-(4-indolyloxy)-3-(4-hydroxy-4-naphthylpiperidin-1-yl)propanes are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1. sub. A receptor, yet lack mutagenic potential as measured by assays of chromosomal aberration. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

US Patent:

59624744, Oct 5, 1999

Filed:

Nov 24, 1997

Appl. No.:

8/977526

Inventors:

James Edmund Audia - Indianapolis IN
Bruce Anthony Dressman - Indianapolis IN
James Joseph Droste - Indianapolis IN
James Erwin Fritz - Greenwood IN
Stephen Warren Kaldor - Indianapolis IN
Daniel James Koch - Indianapolis IN
Joseph Herman Krushinski - Indianapolis IN
Jeffrey Scott Nissen - Indianapolis IN
Vincent Patrick Rocco - Indianapolis IN
John Mehnert Schaus - Zionsville IN
Dennis Charles Thompson - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31445
A61K 3140
C07D40104

US Classification:

514323

Abstract:

This invention provides novel 5-HT. sub. 1F agonists of Formula I ##STR1## where A--B, R,R. sup. 1 and X are as defined in the specification, which are useful for the treatment of migraine and associated disorders.